219 related articles for article (PubMed ID: 23459190)
21. Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways.
Raber PL; Thevenot P; Sierra R; Wyczechowska D; Halle D; Ramirez ME; Ochoa AC; Fletcher M; Velasco C; Wilk A; Reiss K; Rodriguez PC
Int J Cancer; 2014 Jun; 134(12):2853-64. PubMed ID: 24259296
[TBL] [Abstract][Full Text] [Related]
22. Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly.
Serafini P
Immunol Res; 2013 Dec; 57(1-3):172-84. PubMed ID: 24203443
[TBL] [Abstract][Full Text] [Related]
23. Neutrophils at work.
Nauseef WM; Borregaard N
Nat Immunol; 2014 Jul; 15(7):602-11. PubMed ID: 24940954
[TBL] [Abstract][Full Text] [Related]
24. Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade.
Ouzounova M; Lee E; Piranlioglu R; El Andaloussi A; Kolhe R; Demirci MF; Marasco D; Asm I; Chadli A; Hassan KA; Thangaraju M; Zhou G; Arbab AS; Cowell JK; Korkaya H
Nat Commun; 2017 Apr; 8():14979. PubMed ID: 28382931
[TBL] [Abstract][Full Text] [Related]
25. Neutrophils and Granulocytic MDSC: The Janus God of Cancer Immunotherapy.
Zilio S; Serafini P
Vaccines (Basel); 2016 Sep; 4(3):. PubMed ID: 27618112
[TBL] [Abstract][Full Text] [Related]
26. Drafting the proteome landscape of myeloid-derived suppressor cells.
Gato M; Blanco-Luquin I; Zudaire M; de Morentin XM; Perez-Valderrama E; Zabaleta A; Kochan G; Escors D; Fernandez-Irigoyen J; Santamaría E
Proteomics; 2016 Jan; 16(2):367-78. PubMed ID: 26403437
[TBL] [Abstract][Full Text] [Related]
27. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.
Schouppe E; Mommer C; Movahedi K; Laoui D; Morias Y; Gysemans C; Luyckx A; De Baetselier P; Van Ginderachter JA
Eur J Immunol; 2013 Nov; 43(11):2930-42. PubMed ID: 23878002
[TBL] [Abstract][Full Text] [Related]
28. Complexity and challenges in defining myeloid-derived suppressor cells.
Damuzzo V; Pinton L; Desantis G; Solito S; Marigo I; Bronte V; Mandruzzato S
Cytometry B Clin Cytom; 2014 Nov; ():. PubMed ID: 25425222
[TBL] [Abstract][Full Text] [Related]
29. Can the suppressive activity of myeloid-derived suppressor cells be "chop"ped?
Condamine T; Gabrilovich DI
Immunity; 2014 Sep; 41(3):341-342. PubMed ID: 25238087
[TBL] [Abstract][Full Text] [Related]
30. Myeloid regulatory cells in tumor spreading and metastasis.
Keskinov AA; Shurin MR
Immunobiology; 2015 Feb; 220(2):236-42. PubMed ID: 25178934
[TBL] [Abstract][Full Text] [Related]
31. The role of myeloid-derived suppressor cells in immune ontogeny.
Gantt S; Gervassi A; Jaspan H; Horton H
Front Immunol; 2014; 5():387. PubMed ID: 25165466
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapeutic targeting of cancer-induced immunosuppressive cells.
Alizadeh D; Larmonier N
Cancer Res; 2014 May; 74(10):2663-8. PubMed ID: 24778417
[TBL] [Abstract][Full Text] [Related]
33. Myeloid-derived suppressor cells in the development of lung cancer.
Ortiz ML; Lu L; Ramachandran I; Gabrilovich DI
Cancer Immunol Res; 2014 Jan; 2(1):50-8. PubMed ID: 24778162
[TBL] [Abstract][Full Text] [Related]
34. Blockade of CXCR2 signalling: a potential therapeutic target for preventing neutrophil-mediated inflammatory diseases.
Boppana NB; Devarajan A; Gopal K; Barathan M; Bakar SA; Shankar EM; Ebrahim AS; Farooq SM
Exp Biol Med (Maywood); 2014 May; 239(5):509-18. PubMed ID: 24625439
[TBL] [Abstract][Full Text] [Related]
35. Myeloid-derived suppressor cells: Cellular missiles to target tumors.
Chandra D; Gravekamp C
Oncoimmunology; 2013 Nov; 2(11):e26967. PubMed ID: 24427545
[TBL] [Abstract][Full Text] [Related]
36. Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients.
Heuvers ME; Muskens F; Bezemer K; Lambers M; Dingemans AC; Groen HJM; Smit EF; Hoogsteden HC; Hegmans JPJJ; Aerts JGJV
Lung Cancer; 2013 Sep; 81(3):468-474. PubMed ID: 23850196
[TBL] [Abstract][Full Text] [Related]
37. Myeloid-derived suppressor cells in cancer: recent progress and prospects.
Khaled YS; Ammori BJ; Elkord E
Immunol Cell Biol; 2013 Sep; 91(8):493-502. PubMed ID: 23797066
[TBL] [Abstract][Full Text] [Related]
38. Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells.
Zhou J; Nefedova Y; Lei A; Gabrilovich D
Semin Immunol; 2018 Feb; 35():19-28. PubMed ID: 29254756
[TBL] [Abstract][Full Text] [Related]
39. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards.
Bronte V; Brandau S; Chen SH; Colombo MP; Frey AB; Greten TF; Mandruzzato S; Murray PJ; Ochoa A; Ostrand-Rosenberg S; Rodriguez PC; Sica A; Umansky V; Vonderheide RH; Gabrilovich DI
Nat Commun; 2016 Jul; 7():12150. PubMed ID: 27381735
[TBL] [Abstract][Full Text] [Related]
40. Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets.
Lang S; Bruderek K; Kaspar C; Höing B; Kanaan O; Dominas N; Hussain T; Droege F; Eyth C; Hadaschik B; Brandau S
Clin Cancer Res; 2018 Oct; 24(19):4834-4844. PubMed ID: 29914893
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
